First-in-Human cancer vaccine trial seeks to train immune system to fight rare tumors
NCT ID NCT03879694
Summary
This early-stage study tested the safety and immune effects of a new cancer vaccine called SurVaxM in 19 patients with advanced neuroendocrine tumors that had spread. The vaccine aims to teach the body's immune system to recognize and attack cancer cells by targeting a protein called survivin, which is often found on tumor cells. Patients received the vaccine along with standard hormone therapy to see if it could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ATYPICAL CARCINOID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.